April 28, 2026 - The U.S. Food and Drug Administration has released a sweeping revision to its biosimilar development guidance that fundamentally changes the economics of bringing biosimilar products to market. The March 2026 update - formally titled "New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)" - eliminates the default requirement for a three-way pharmacokinetic (PK) bridging study, a regulatory hurdle that has added millions of dollars and years of development time to biosimilar programs. For API suppliers, contract development and manufacturing organizations (CDMOs), and finished dosage form (FDF) manufacturers, this guidance signals a new era of accelerated biosimilar competition.
Under the previous regulatory framework, biosimilar sponsors seeking to use clinical data generated with a foreign-licensed comparator product were required to conduct a three-way PK bridging study. This study mandated direct comparison among three products: the proposed biosimilar, the U.S.-licensed reference product, and the foreign-licensed comparator. The rationale was to establish a scientific bridge demonstrating that the foreign comparator was sufficiently similar to the U.S. reference product to support extrapolation of clinical data.
In practice, this requirement imposed significant burdens. Each three-way PK study typically cost between $1 million and $2 million, and these costs multiplied across sponsors and jurisdictions. For large, multicenter global studies, sourcing sufficient quantities of U.S.-licensed reference product - which is often more expensive and harder to procure than its foreign counterpart - added further logistical complexity. The cumulative effect was that biosimilar development programs routinely cost $100 million to $200 million per product, effectively limiting participation to large multinational pharmaceutical companies.
The FDA's March 2026 revision makes three transformative changes:
1. Elimination of the Three-Way PK Bridging Default. Sponsors may now justify the relevance of clinical data generated with a foreign comparator through robust scientific rationale, advanced analytical data, and publicly available information. The FDA no longer presumes that a three-way study is necessary.
2. Acceptance of Non-U.S. Comparator Clinical Data. Comparative clinical data generated using a comparator product approved outside the United States may now support a demonstration of biosimilarity, provided the sponsor demonstrates scientific justification. This aligns the U.S. framework more closely with the European Medicines Agency's (EMA) established practice.
3. Removal of Comparative Efficacy Studies as Default. Building on its October 2025 draft guidance, the FDA has further codified that comparative efficacy studies are no longer the default requirement for biosimilar approval. Analytical comparison data, PK data, and immunogenicity data can now serve as the primary evidence of biosimilarity.
The FDA estimates these changes could save developers up to 50% of PK study costs - potentially $20 million or more per program.
The FDA's updated guidance reflects growing confidence in the power of modern analytical characterization to establish biosimilarity. The agency's own experience has shown that clinical studies have rarely, if ever, detected issues not already identified through analytical methods. For highly purified therapeutic proteins - which constitute the majority of blockbuster biologics facing patent expiration - analytical and PK data can serve as a reliable surrogate for clinical efficacy and safety data.
This position is supported by extensive regulatory experience. The FDA has now approved over 90 biosimilars across 20 unique biological molecules, and this body of evidence has demonstrated that the analytical framework is robust. As the agency stated, the shift toward analytical characterization is consistent with its recent policy changes regarding interchangeability, where the focus has moved away from extensive clinical switching studies.
For API suppliers and CDMOs operating in the biosimilar space, the FDA's guidance has several concrete implications:
Expanded Addressable Market. By lowering development costs, the guidance opens biosimilar development to smaller biotechnology companies that previously could not afford to participate. This expands the pool of potential customers for API suppliers and CDMO partners.
Accelerated Timelines. Eliminating three-way PK studies and comparative efficacy studies can shave 12-24 months off development timelines. API suppliers may see earlier demand signals and shorter lead times for commercial supply agreements.
Global Program Efficiency. The ability to use a single reference product across multiple jurisdictions enables the design of global clinical programs that reduce duplication and facilitate simultaneous launches in the U.S., EU, and other major markets. This favors CDMOs with integrated global manufacturing networks.
Quality Expectations Rise. As the regulatory framework shifts toward analytical characterization as the primary evidence of biosimilarity, the quality and consistency of API manufacturing become even more critical. CDMOs with advanced analytical capabilities and robust quality systems will be best positioned to support biosimilar developers under the new framework.
The FDA's guidance arrives at a critical moment. More than $200 billion in annual biologic revenues are at risk due to patent expirations by 2030. Major products including Keytruda (pembrolizumab), Opdivo (nivolumab), and Stelara (ustekinumab) are approaching or have reached loss of exclusivity. The global biosimilars market, already valued at approximately $30 billion in 2024, could generate over $180 billion in U.S. healthcare savings in the coming years.
With development costs potentially dropping from $100-200 million to $50-100 million per product, the economics of biosimilar development fundamentally change. Specialized manufacturers - particularly those in Asia with strong cost structures - may find new opportunities to enter markets previously dominated by large Western pharmaceutical companies.
Despite the landmark reforms, two policy gaps remain. First, the FDA has yet to authorize the United States Pharmacopeia (USP) to develop standardized product specifications for biologics, which would further reduce the need for expensive reference-product comparisons. Second, "patent doping" - the practice by originator manufacturers of filing cascades of secondary patents to extend effective market exclusivity - continues to delay biosimilar entry even after regulatory approval.
Both issues are the subject of ongoing advocacy and regulatory proceedings, and their resolution could further accelerate biosimilar competition in the coming years.
For API suppliers, CDMOs, and FDF manufacturers, the FDA's March 2026 biosimilar guidance is a clear signal to invest in analytical capabilities, quality systems, and global manufacturing capacity. The barriers to biosimilar entry are falling, and the wave of biologic patent expirations is approaching. Companies that position themselves now - with the technical expertise, regulatory knowledge, and manufacturing infrastructure to support accelerated biosimilar development programs - will be best positioned to capture value in this rapidly evolving market.
The question is no longer whether the biosimilar wave will arrive, but whether your organization is ready to ride it.
